Skip to main content

Table 5 Correlation of circRNAs relative expression with treatment response

From: Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma

circRNAs

CR

Non-CR

P value

ORR

Non-ORR

P value

Circ-PTK2, No. (%)

  

0.015

  

0.559

 High

3 (10.0)

27 (90.0)

 

21 (70.0)

9 (30.0)

 

 Low

11 (36.7)

19 (63.3)

 

23 (76.7)

7 (23.3)

 

Circ-ATIC, No. (%)

  

0.222

  

0.559

 High

9 (30.0)

21 (70.0)

 

21 (70.0)

9 (30.0)

 

 Low

5 (16.7)

25 (83.3)

 

23 (76.7)

7 (23.3)

 

Circ-RNF217, No. (%)

  

0.222

  

0.020

 High

5 (16.7)

25 (83.3)

 

18 (60.0)

12 (40.0)

 

 Low

9 (30.0)

21 (70.0)

 

26 (86.7)

4 (13.3)

 

Circ-RERE, No. (%)

  

1.000

  

0.559

 High

7 (23.3)

23 (76.7)

 

21 (70.0)

9 (30.0)

 

 Low

7 (23.3)

23 (76.7)

 

23 (76.7)

7 (23.3)

 

Circ-SETD5, No. (%)

  

0.173

  

0.029

 High

5 (16.1)

26 (83.9)

 

19 (61.3)

12 (38.7)

 

 Low

9 (31.0)

20 (69.0)

 

25 (86.2)

4 (13.8)

 

Circ-NAGPA, No. (%)

  

1.000

  

0.559

 High

7 (23.3)

23 (76.7)

 

21 (70.0)

9 (30.0)

 

 Low

7 (23.3)

23 (76.7)

 

23 (76.7)

7 (23.3)

 

Circ-KCNQ5, No. (%)

  

0.222

  

0.243

 High

5 (16.7)

25 (83.3)

 

24 (80.0)

6 (20.0)

 

 Low

9 (30.0)

21 (70.0)

 

20 (66.7)

10 (33.3)

 

Circ-CSPP1, No. (%)

  

0.067

  

0.559

 High

10 (33.3)

20 (66.7)

 

23 (76.7)

7 (23.3)

 

 Low

4 (13.3)

26 (86.7)

 

21 (70.0)

9 (30.))

 

Circ-SFMBT2, No. (%)

  

0.067

  

1.000

 High

10 (33.3)

20 (66.7)

 

22 (73.3)

8 (26.7)

 

 Low

4 (13.3)

26 (86.7)

 

22 (73.3)

8 (26.7)

 

Circ-UGGT2, No. (%)

  

0.542

  

0.243

 High

8 (26.7)

22 (73.3)

 

24 (80.0)

6 (20.0)

 

 Low

6 (20.0)

24 (80.0)

 

20 (66.7)

10 (33.3)

 

Circ-AFF2, No. (%)

  

0.002

  

0.559

 High

12 (40.0)

18 (60.0)

 

23 (76.7)

7 (23.3)

 

 Low

2 (6.7)

28 (93.3)

 

21 (70.0)

9 (30.0)

 

Circ-WWC3, No. (%)

  

0.222

  

0.080

 High

5 (16.7)

25 (83.3)

 

19 (63.3)

11 (36.7)

 

 Low

9 (30.0)

21 (70.0)

 

25 (83.3)

5 (16.7)

 

Circ-SLAIN1, No. (%)

  

0.222

  

0.559

 High

5 (16.7)

25 (83.3)

 

21 (70.0)

9 (30.0)

 

 Low

9 (30.0)

21 (70.0)

 

23 (76.7)

7 (23.3)

 

Circ-WDR37–1, No. (%)

  

0.542

  

0.559

 High

6 (20.0)

24 (80.0)

 

23 (76.7)

7 (23.3)

 

 Low

8 (26.7)

22 (73.3)

 

21 (70.0)

9 (30.0)

 

Circ-WDR37–2, No. (%)

  

0.640

  

0.185

 High

8 (25.8)

23 (74.2)

 

25 (80.6)

6 (19.4)

 

 Low

6 (20.7)

23 (79.3)

 

19 (65.5)

10 (34.5)

 

Circ-DNAJC5, No. (%)

  

0.222

  

0.243

 High

5 (16.7)

25 (83.3)

 

20 (66.7)

10 (33.3)

 

 Low

9 (30.0)

12 (70.0)

 

24 (80.0)

6 (20.0)

 

Circ-KLHL2, No. (%)

  

0.542

  

0.559

 High

6 (20.0)

24 (80.0)

 

23 (76.7)

7 (23.3)

 

 Low

8 (26.7)

22 (73.3)

 

21 (70.0)

9 (30.0)

 

Circ-IQGAP1, No. (%)

  

0.542

  

0.243

 High

6 (20.0)

24 (80.0)

 

24 (80.0)

6 (20.0)

 

 Low

8 (26.7)

22 (73.3)

 

20 (66.7)

10 (33.3)

 

Circ-AL137655, No. (%)

  

1.000

  

0.080

 High

7 (23.3)

23 (76.7)

 

25 (83.3)

5 (16.7)

 

 Low

7 (23.3)

23 (76.7)

 

19 (63.3)

11 (36.7)

 

Circ-ASAP1, No. (%)

  

0.542

  

0.559

 High

6 (20.0)

24 (80.0)

 

21 (70.0)

9 (30.0)

 

 Low

8 (26.7)

22 (73.3)

 

23 (76.7)

7 (23.3)

 
  1. Comparisons were determined by Chi-square test. P value < 0.05 was considered significant. CR complete response, ORR overall response rate. The number in boldface represented statistically significant P values